Malignant histiocytosis (true histiocytic lymphoma) clinicopathological study of 25 cases
Stefano Pileri(European Institute of Oncology), S Tura(University of Bologna), Domenica Taruscio(Istituto Superiore di Sanità), Giovanna Cavazzini(University of Padua), Giovanni Martinelli(University of Bologna), Marco Gobbi(Istituto di Ematologia di Bologna), Patrizio Mazza(Ospedale SS. Annunziata), F. Lauria(Istituto di Ematologia di Bologna), M.T. Rivano(University of Bologna)
Cited by 46
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
ALK+ lymphoma: clinico-pathological findings and outcome.
|PubMed|1999|569